Aneuploidy doesn't just happen—it actively selects for the genes that kill
For decades, cancer biologists have wrestled with a paradox: how do the most aggressive tumors so reliably acquire the very mutations that make them lethal, when cellular chaos would seem to work against such precision? Researchers at Sinai Health have now traced the answer to aneuploidy — the abnormal multiplication of chromosomes — revealing that this apparent disorder is itself a selective force, one that amplifies the genes most useful to a cancer's survival. In mapping this mechanism within basal-like breast cancer, one of the disease's deadliest forms, the team uncovered 90 driver genes, 81 of them never before linked to the disease, offering a dramatically expanded landscape for therapeutic intervention.
- Basal-like breast cancer kills with particular efficiency, and patients have long faced a narrow corridor of treatment options while the disease resists chemotherapy and outpaces conventional strategies.
- The central mystery — why aggressive tumors so consistently acquire the same lethal mutations despite the randomness of cellular mutation — has haunted cancer biology for years without a satisfying answer.
- Sinai Health researchers used mouse models to demonstrate that aneuploidy is not passive chaos but an active selective pressure, duplicating and amplifying whichever genes give cancer cells a competitive edge, accelerating evolution from millennia into months.
- The study identified 90 genes driving basal-like breast cancer, with 81 representing entirely new territory — concrete, actionable targets that give researchers and drug developers a far larger toolkit than existed before.
- While no clinic changes overnight, the findings point toward a future of more precisely tailored therapies, and some newly identified gene targets may already be vulnerable to existing drugs.
For years, a fundamental question has haunted cancer biology: why do aggressive breast cancers so reliably acquire the specific mutations that make them deadly, when cellular mutation is supposed to be random? A new study from Sinai Health has answered that question — and in doing so, has revealed 81 previously unknown targets for treatment.
The research centered on basal-like breast cancer, one of the most lethal subtypes of the disease. Using mouse models, scientists examined how the cancer develops, focusing on aneuploidy — the presence of an abnormal number of chromosomes in cancer cells. What they found overturned the assumption that aneuploidy is simply a byproduct of cellular chaos. Instead, it functions as a selective pressure: when cells develop abnormal chromosome counts, certain genes are more likely to be duplicated or amplified, and those that accelerate cancer growth gain a competitive advantage. The result is something like evolution in fast-forward — months or years instead of millennia.
The team identified 90 driver genes in total, but the striking figure is 81 — the number of those genes that had never before been connected to basal-like breast cancer. These are not obscure molecular footnotes. They represent actionable targets, and some may already be vulnerable to existing drugs, while others could inspire entirely new therapeutic approaches.
For patients, the stakes are high. Basal-like breast cancer carries significantly lower survival rates than other subtypes, and resistance to chemotherapy is common. These findings won't change what happens in a clinic tomorrow, but they reframe how researchers can think about the disease — not as a chaos of random mutations, but as a system shaped by aneuploidy's selective logic. Understanding that logic opens a new chapter in the effort to defeat one of cancer's most formidable forms.
For years, researchers have puzzled over a fundamental question: why do certain cells in aggressive breast cancers acquire the specific mutations that make them so deadly? A new study conducted at Sinai Health offers an answer, and in doing so, has opened a door to 81 previously unknown treatment targets.
The research focused on basal-like breast cancer, one of the most lethal forms of the disease. Scientists used mouse models to trace how this cancer develops and spreads, paying particular attention to a phenomenon called aneuploidy—an abnormal number of chromosomes in cancer cells. What they discovered was that aneuploidy doesn't just happen randomly in these tumors. Instead, it actively selects for the acquisition of driver genes, the specific mutations that fuel the cancer's aggression and resistance to treatment.
The team identified 90 genes in total that drive basal-like breast cancer. What makes this finding significant is that 81 of those 90 genes had never before been connected to the disease. These weren't obscure molecular footnotes either—they represent concrete, actionable targets for therapeutic intervention. For a cancer subtype that has historically offered patients limited options, this expansion of the genetic landscape could reshape how doctors approach treatment.
The mystery the researchers solved was essentially this: cancer cells are chaotic, prone to random mutations. Yet somehow, certain mutations appear far more frequently in aggressive tumors than chance alone would predict. The answer lies in aneuploidy's selective pressure. When cancer cells develop abnormal chromosome numbers, they create an environment where certain genes are more likely to be duplicated or amplified. Those genes that happen to accelerate cancer growth get selected for—they give the cell a competitive advantage, so they persist and spread. It's evolution in fast-forward, playing out over months or years instead of millennia.
This understanding matters because it suggests a new way to think about cancer prevention and treatment. If aneuploidy is the mechanism driving gene acquisition, then targeting the genes it selects for becomes a rational strategy. The 81 newly identified targets offer researchers and pharmaceutical companies a much larger toolkit than they had before. Some of these genes might be vulnerable to existing drugs. Others might inspire entirely new therapeutic approaches.
Basal-like breast cancer remains among the most aggressive subtypes, with survival rates significantly lower than other forms of the disease. Patients diagnosed with it often face a narrow range of treatment options, and resistance to chemotherapy is common. The new findings don't immediately change what happens in a clinic tomorrow, but they point toward a future where treatment could be more precisely tailored to the genetic architecture of each patient's tumor.
The work represents the kind of fundamental research that can take years to translate into clinical practice. But it answers a question that has haunted cancer biology for decades: how does aneuploidy, which seems like a liability for a cell, actually become an asset for a cancer? The answer—that it selects for the genes that matter most—opens a new chapter in understanding and potentially defeating one of cancer's deadliest forms.
Citas Notables
Aneuploidy selects for the acquisition of driver genes in breast cancer— Study published in Nature
La Conversación del Hearth Otra perspectiva de la historia
So aneuploidy is just having the wrong number of chromosomes. Why would that help a cancer cell survive?
Because it's not random. When a cell has abnormal chromosome numbers, certain genes get copied more often. If one of those extra copies happens to be a gene that makes the cancer grow faster, that cell outcompetes its neighbors. It's selection at the molecular level.
And that's what they found—that this selection process was picking specific genes over and over?
Exactly. They looked at 90 genes driving basal-like breast cancer and found that 81 of them had never been documented before. That means researchers were missing most of the actual targets because they weren't looking at the problem through the lens of aneuploidy.
Does this mean we can now treat basal-like breast cancer better?
Not immediately. But it gives us 81 new places to aim. Some of those genes might already be druggable with existing therapies. Others might inspire new ones. The real value is that we're no longer guessing in the dark.
Why is basal-like breast cancer so deadly compared to other types?
It's aggressive, it spreads quickly, and it's often resistant to standard chemotherapy. Patients have fewer good options. That's why finding new targets matters so much—these patients need better tools.
How long until this becomes a treatment?
That's the hard part. This is foundational research. It could take years to develop drugs against these targets, test them, and get them approved. But without understanding the mechanism first, you're just throwing darts.